T
he gene coding for the endotoxin receptor TLR4 (toll-like receptor 4) has been sequenced recently, and the polymorphic spectrum of the gene has been elucidated (1) . A polymorphism in the gene affects the inflammatory response to lipopolysaccharide (LPS) (2, 3) , with impact on the risk of gramnegative infections and septic shock (4, 5) . We have analyzed two cosegregating mutations in the gene region coding for the extracellular domain of the endotoxin receptor TLR4, characterized by a substitution at amino acid position 299 (glycine for aspartate) and another at position 399 (isoleucine for threonine). The 299Gly form of TLR4 affects the inflammatory response to LPS by exhibiting attenuated signaling leading to a dampened response to LPS (4, 5) . Polymorphisms in the TLR4 protein show an increased risk to develop a septic shock with gramnegative microorganisms (6) , premature birth (7) , and graft versus host disease after hematopoietic stem cell transplantation (8) .
Polymorphisms in the TLR4 gene, however, did not reveal any association with severity of menigococcal disease (9), risk of premature rupture of membranes caused by infections (10), or asthma-and atopy-related diseases (11) .
TLR4 interacts with endogenous ligands such as the stress protein hsp60 (12) . Since hsp60 is an important player in chronic inflammatory conditions (12) , the TLR4 polymorphism may regulate the subclinical inflammation underlying the pathogenesis of arteriosclerosis.
Indeed, a recent study reported an association of the TLR4 polymorphism with atherogenesis (13) . Subjects carrying the rare 299Gly allele exhibited a lower risk of carotid atherosclerosis and a smaller intima-media thickness in the common carotid artery (13) .
Parameters of mild systemic inflammation observed in association with atherosclerosis are strikingly similar to what is seen in subjects with metabolic syndrome or type 2 diabetes, notably elevated serum levels of acute-phase proteins, some inflammatory cytokines, and soluble adhesion molecules (14 -17) . We therefore analyzed for an association of the TLR4 gene polymorphism with features of the metabolic syndrome or with overt type 2 diabetes.
Statistical analysis. The nonparametrical Kruskal-Wallis test was performed to test for association with characteristics of subclinical inflammation. All other variables were analyzed with ANOVA for continuous end points and logistic regression for discrete end points. All models were adjusted for age and sex.
RESULTS AND DISCUSSION
As observed by Kiechl et al. (13) , the Asp299Gly and Thr399Ile polymorphisms were in linkage disequilibrium Data are means Ϯ SD or median (interquartile range). The respective P values result from the nonparametric Kruskal-Wallis test, while associations with the genotype were searched with logistic regression. Essentially the same outcomes were noted when means Ϯ SD were used for statistical evaluation. The groups were matched for age and sex. Only groups of subjects that were both genotyped and phenotyped were analyzed. Data are means Ϯ SD or median (interquartile range). The first two columns display the frequencies of hyptertensive and nonhypertensive subjects in both genotype groups in the first row. The P value for hypertension was taken from analysis with a logistic regression model; the remaining components of the metabolic syndrome were analysed with ANOVA. All models were adjusted for age and sex. The P values belonging to the components of subclinical systemic inflammation were obtained with the Kruskal-Wallis test. Essentially the same outcomes were noted when means Ϯ SD were used for statistical evaluation. Separate analyses of men or women or of type 2 diabetic cases and IGT subjects only also showed no association with the TLR4 polymorphism. *Hypertension was defined as systolic blood pressure Ն140 mmHg, diastolic blood pressure Ն90 mmHg, or current antihypertensive treatment. †108 patients with diabetes provided non fasting blood samples and were excluded.
in Ͼ90% of cases. Therefore, we report the analyses with regard to the Asp299Gly polymorphism only. Results for the polymorphism at amino acid 399 provided were not different. However, the functional defect of TLR4 is largely caused by the amino acid substitution at position 299. Genotype analysis of the polymorphism resulting in an Asp299Gly exchange was possible in 671 of the 722 subjects leading to a call rate of 92.9%. The Asp299/Asp299 was observed in 599 cases (89.3%), the heterozygous type Asp299/299Gly was found in 70 cases (10.4%), and the homozygous type 299Gly/299Gly in 2 cases (0.3%). A bias due to the genotyping rate of 92.9% appears unlikely because both single nucleotide polymorphisms were in Hardy Weinberg equilibrium and the data are very similar to previously published data (13) .
The group with type 2 diabetes or IGT exhibited characteristics of subclinical inflammation with elevated systemic levels of IL-6, IL-6 receptor, CRP, SAA, or fibrinogen (Table 1 ). This higher state of activation of innate immunity was not accompanied by a bias toward the high LPS responder type (TLR4 major allele, Table 1 ). In this context it should be noted that individuals taking antiinflammatory drugs were not excluded because, in the age-group studied, a large fraction were taking such substances, including statins, antihypertensive medication, and antidiabetic drugs. The impact of such therapy appears limited because systemic levels of inflammatory mediators are elevated in individuals with type 2 diabetes, metabolic syndrome, or atherosclerosis (14) despite their more frequent use of such drugs.
Next, we analyzed for an association of the TLR4 polymorphism with individual parameters of the metabolic syndrome or of subclinical inflammation. Subjects with one or two alleles causing the 299Gly TLR4 did not differ from carriers of TLR4 Asp homozygotes with regard to hypertension, BMI, waist circumference, or HDL cholesterol levels (Table 2) . Differences were also not observed for systemic levels of IL-6, IL-6 receptor, CRP, SAA, or fibrinogen (Table 2) . Of all parameters analyzed, only the prevalence of hypertension showed a trend (P ϭ 0.07), leaving the possibility of a mild protective effect of the Gly299 TLR4 allele. A similar analysis only regarding control and IGT subjects also failed to show an association between TLR4 genotype and metabolic or immunologic phenotype ( Table 3) .
The data do not confirm TLR4 allele-dependent differences in systemic IL-6 or fibrinogen concentrations reported for the Bruneck Study (13) . Both the Bruneck and our study share basic characteristics of population-based sampling and a similar age range (40 -80 vs. 55-74 years) and number of subjects studied. Methodological aspects probably do not account for the difference because a number of inflammatory markers were assessed in both studies. None of these came close to the significance level in our study, while most parameters did so in the Bruneck Study. A reason for this difference could not be identified; in theory small differences may be expected with regard to the genetic background, environmental factors (such as low level infections), or the sampling procedure. In this context it is noteworthy that almost all carriers of TLR4 Data are means Ϯ SD or median (interquartile range). Analyses are performed as in Table 2 . The first two columns display the frequencies of hyptertensive and nonhypertensive subjects in both genotype groups in the first row. For further components of the metabolic syndrome, means Ϯ SD are shown, and the median and quartiles are shown for markers of subclinical inflammation. P values were obtained with a logistic regression model for hypertension, with ANOVA for the remaining components of the metabolic syndrome and with the Kruskal-Wallis test for components of subclinical systemic inflammation. All models were adjusted for age and sex. *Hypertension was defined as systolic blood pressure Ն140 mmHg, diastolic blood pressure Ն90 mmHg, or current antihypertensive treatment.
299Gly allele are heterozygous and hence coexpress the fully functional TLR4 Asp299. Monocytes heterozygous for TLR4 do not exhibit deficient responses to LPS (3, 21) . Independent of this issue, the important finding of our KORA study is that there is no strong impact of the TLR4 polymorphism on major features of the metabolic syndrome.
